Proof-of-concept Multicentre, Prospective, Randomised, Open-label and Parallel Group Clinical Trial to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5 mg Six-monthly in Patients With Recurrence of Prostate Cancer Previously Treated With Radiotherapy.
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms ANABRAQ
- Sponsors Ipsen
- 10 Jun 2017 Biomarkers information updated
- 02 Apr 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 14 Nov 2014 New source identified and integrated: European Clinical Trials Database record.